Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine, Lisaftoclax, and Azacitidine in AML After Venetoclax Failure
NCT07813390Phase 2Enrolling by invitation
- Sponsor
- Guangdong Second Provincial General Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by Guangdong Second Provincial General Hospital. Primary endpoint: Overall Response Rate at 8 weeks. Started Sep 2026; status: enrolling by invitation.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07813390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07813390.